<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483054</url>
  </required_header>
  <id_info>
    <org_study_id>210041000824904203</org_study_id>
    <nct_id>NCT00483054</nct_id>
  </id_info>
  <brief_title>Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin</brief_title>
  <acronym>N2R</acronym>
  <official_title>Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bamrasnaradura Infectious Diseases Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bamrasnaradura Infectious Diseases Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The randomized controlled trial is conducted among antiretroviral naive co-infected HIV and
      tuberculosis patients who receiving rifampicin-based antituberculous regimen fro at least 4
      weeks butt not exceed 16 weeks before enrolment. All patients receive the same backbone
      regimen of stavudine (30 mg/40 mg twice daily)+ lamivudie 150 mg twice daily. They are
      randomized to receive nevirapine 400 mg/day twice daily vs efavirenz 600 mg/day at bed time.
      All patients are followed through 144 weeks after initiation of antiviral therapy. The
      primary objective are to compare the proportion of patient who achieve undetectable plasma
      HIV-1RNA&lt;50 copies/ml at week 48. The previous reports demonstrated that the standard doses
      of both nevirapine and efavirenz coulde be used among co-infected HIV and tuberculosis
      patients who receiving rifampicin even though plasma levels are somewhat reduced by
      rifampicin. However, there have been not been a randomized control trial to compare these two
      regimens. Thus, this trial will provide the efficacy data between these two regimens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare proportion of patients who achieved undetectable plasma HIV-1RNA&lt; 50 copies/mL at 48 weeks after initiation of antiretroviral treatment between the 2 groups</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to compare CD4 response at 48, 96 and 144 weeks after initiation of antiretroviral treatment, to compare adverse drugs reaction between the 2 groups</measure>
    <time_frame>144 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>HIV Infections</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Efavirenz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Efavirenz 600 mg/day + stavudine +lamivudine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nevirapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nevirapine 400 mg/day + stavudine +lamivudine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz</intervention_name>
    <description>efavirenz 600 mg/day + stavudine + lamivudine</description>
    <arm_group_label>Efavirenz</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nevirapine</intervention_name>
    <description>nevirapine 400 mg/day + stavudine +lamivudine</description>
    <arm_group_label>Nevirapine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-60 years

          -  Positive Serology for HIV-1

          -  Na√Øve to antiretroviral therapy

          -  Baseline CD4 cell counts &lt;250 cells/mm3

          -  Diagnosed active tuberculosis by clinical features and/or positive acid fast stain
             and/or positive culture

          -  Received rifampicin at least 4 weeks but not exceed 16 weeks prior to enrollment

          -  Willing to participate and sign inform consent

        Exclusion Criteria:

          -  Aspartate transferase enzymes (AST) or alanine transminase enzyme (ALT) &gt;5 times of
             upper limit

          -  total bilirubin &gt;3 times of upper limit

          -  serum creatinine) &gt;2 times of upper limit

          -  pregnancy or lactation

          -  receiving immunosuppressive drugs

          -  receiving any drugs that may have drug-drug interaction with nevirapine and rifampicin

          -  chronic alcoholic drunken and intravenous drug users

          -  Previously received single dose of nevirapine to prevent mother to child transmission

          -  positive for serum cryptococcal antigen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weerawat Manosuthi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bamrasnaradura Infectious Diseases Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bamrasnaradura Infectious Diseases Institute</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2007</study_first_submitted>
  <study_first_submitted_qc>June 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2007</study_first_posted>
  <last_update_submitted>November 21, 2011</last_update_submitted>
  <last_update_submitted_qc>November 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Department of Disease Control</name_title>
    <organization>Ministry of Public Health</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>tuberculosis</keyword>
  <keyword>efavirenz</keyword>
  <keyword>nevirapine</keyword>
  <keyword>rifampicin</keyword>
  <keyword>co-infected HIV and tuberculosis patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Stavudine</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

